MedElevator Войти в исследования
← Поиск публикаций

DOI 10.15326/jcopdf.2023.0425

Медицинская библиотека · Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024

Inhaler Formulary Change in COPD and the Association with Exacerbations, Health Care Utilization, and Costs.

Duan Kevin I, Donovan Lucas M, Spece Laura J, Wong Edwin S, Feemster Laura C, Bryant Alexander D, Plumley Robert, Crothers Kristina, Au David H

СтатьяПеревод в очереди

Аннотация

RATIONALE: Prescription formularies specify which medications are available to patients. Formularies change frequently, potentially forcing patients to switch medications for nonclinical indications (nonmedical switching). Nonmedical switching is known to impact disease control and adherence. The consequences of nonmedical switching have not been rigorously studied in COPD.

METHODS

We conducted a cohort study of Veterans with COPD on inhaler therapy in January 2016 when formoterol was removed from the Department of Veterans Affairs (VA) national formulary. A 2-point difference-in-differences analysis using multivariable negative binomial and generalized linear models was performed to estimate the association of the formulary change with patient outcomes in the 6 months before and after the change. Our primary outcome was the number of COPD exacerbations in 6 months, with secondary outcomes of total health care encounters and encounter-related costs in 6 months.

RESULTS

We identified 10,606 Veterans who met our inclusion criteria, of which 409 (3.9%) experienced nonmedical switching off formoterol. We did not identify a change in COPD exacerbations (-0.04 exacerbations; 95% confidence interval [CI] -0.12, 0.03) associated with the formulary change. In secondary outcome analysis, we did not observe a change in the number of health care encounters (-0.12 visits; 95% CI -1.00, 0.77) or encounter-related costs ($369; 95% CI -$1141, $1878).

CONCLUSIONS

Among COPD patients on single inhaler therapy, nonmedical inhaler switches due to formulary discontinuation of formoterol were not associated with changes in COPD exacerbations, encounters, or encounter-related costs. Additional research is needed to confirm our findings in more severe disease and other settings.

Для цитирования: Duan Kevin I, Donovan Lucas M, Spece Laura J, Wong Edwin S, Feemster Laura C, Bryant Alexander D, Plumley Robert, Crothers Kristina, Au David H. Inhaler Formulary Change in COPD and the Association with Exacerbations, Health Care Utilization, and Costs.. Chronic obstructive pulmonary diseases (Miami, Fla.). 2024. DOI: 10.15326/jcopdf.2023.0425.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.